Dr. Godsey has 30 yrs experience in the in vitro diagnostic industry. During the first phase of his career, Dr. Godsey led R&D organizations that developed industry first automated systems in clinical microbiology and infectious disease at Dade Behring/MicroScan and Gen-Probe/Hologic (TIGRIS System). Dr. Godsey went on to focus on Oncology Dx with R&D leadership roles at Veridex/JNJ (CTCs), Digene/Qiagen (HPV) and Roche Ventana Medical Tissue Dx.

In 2015 Dr. Godsey joined Thermo Fisher Scientific where he built out the Clinical Sequencing Division and its portfolio, gaining the first FDA approval of a multi-variant, multi-drug NGS-based CDX in Oncology. His Team went on the launch the Genexus Platform which automates sample to result reported in <24hrs, with just 2 touch points and the Oncomine Precision Assay, which is a universally formatted test for both Solid Tumor or liquid biopsy testing. From Thermo, Dr. Godsey served at VP, Assay Development at Illumina, launching v1 of the TSO500 Liquid Biopsy test. Dr. Godsey is also an inaugural member and Co-Chair at BloodPAC, who’s mission is the commercialization/clinical implementation of liquid biopsy tests.

In June 2021, Dr. Godsey joined Quest Diagnostics, heading up what is now called MGO R&D, with the mission to bring Genomics and liquid biopsy testing to patients and consumers in need of this life changing information.